JP7069423B2 - 細胞分布に基づく放射線データの較正 - Google Patents
細胞分布に基づく放射線データの較正 Download PDFInfo
- Publication number
- JP7069423B2 JP7069423B2 JP2021539004A JP2021539004A JP7069423B2 JP 7069423 B2 JP7069423 B2 JP 7069423B2 JP 2021539004 A JP2021539004 A JP 2021539004A JP 2021539004 A JP2021539004 A JP 2021539004A JP 7069423 B2 JP7069423 B2 JP 7069423B2
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- cells
- interest
- operating
- computer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005855 radiation Effects 0.000 title claims description 22
- 210000004027 cell Anatomy 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 73
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 230000002503 metabolic effect Effects 0.000 claims description 45
- 238000002600 positron emission tomography Methods 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 26
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims description 21
- 238000003384 imaging method Methods 0.000 claims description 21
- 238000001574 biopsy Methods 0.000 claims description 19
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 14
- 238000009825 accumulation Methods 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 4
- 238000003782 apoptosis assay Methods 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 3
- 230000005522 programmed cell death Effects 0.000 claims description 3
- 238000012937 correction Methods 0.000 claims description 2
- 230000001744 histochemical effect Effects 0.000 claims description 2
- 238000011532 immunohistochemical staining Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 description 113
- 102000008096 B7-H1 Antigen Human genes 0.000 description 26
- 108010074708 B7-H1 Antigen Proteins 0.000 description 26
- 238000002591 computed tomography Methods 0.000 description 22
- 210000004881 tumor cell Anatomy 0.000 description 22
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 17
- 230000004044 response Effects 0.000 description 11
- 230000001575 pathological effect Effects 0.000 description 10
- 239000000700 radioactive tracer Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 6
- 238000012879 PET imaging Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- HIIJZYSUEJYLMX-JZRMKITLSA-N 1-fluoranyl-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound [18F]CC(O)CN1C=CN=C1[N+]([O-])=O HIIJZYSUEJYLMX-JZRMKITLSA-N 0.000 description 2
- 102000005548 Hexokinase Human genes 0.000 description 2
- 108700040460 Hexokinases Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 238000012636 positron electron tomography Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 1-[(2r,4s,5r)-4-fluoranyl-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H]([18F])C1 UXCAQJAQSWSNPQ-ZIVQXEJRSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- -1 acetyl cozyme Chemical compound 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013527 convolutional neural network Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000013275 image-guided biopsy Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
- G06T7/0014—Biomedical image inspection using an image reference approach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5247—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/36—Microscopes arranged for photographic purposes or projection purposes or digital imaging or video purposes including associated control and data processing arrangements
- G02B21/365—Control or image processing arrangements for digital or video microscopes
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10056—Microscopic image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10081—Computed x-ray tomography [CT]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10088—Magnetic resonance imaging [MRI]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10104—Positron emission tomography [PET]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10108—Single photon emission computed tomography [SPECT]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30096—Tumor; Lesion
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Multimedia (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Quality & Reliability (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nuclear Medicine (AREA)
Description
Claims (14)
- 被検者の組織に関連する放射線データを較正するためのコンピュータの作動方法であって、
前記組織の生物学的パラメータを示す生の値を計算するために該組織の放射線画像を分析するステップと、
前記組織の顕微鏡画像を分析して、該組織内の関心細胞の分布を特定するステップと、
前記組織内の関心細胞の生物学的パラメータを示す較正値を計算するステップであって、該較正値が前記生の値を前記組織内の関心細胞の前記特定された分布に基づいて補正することにより得られる、計算するステップと
を有し、
前記放射線画像が、ポジトロン放出断層撮影法により取得され、
前記組織の前記生物学的パラメータを示す前記生の値が、ポジトロン放出断層撮影法の撮像により取得される標準集積値である、コンピュータの作動方法。 - 前記生物学的パラメータが代謝活性を有する、請求項1に記載のコンピュータの作動方法。
- 前記組織の放射線画像を分析して、該組織内の複数の位置における代謝活性を示す生の値を計算するステップと、
前記組織内の複数の位置を、前記顕微鏡画像を分析することにより特定された前記関心細胞の分布と関連付けるステップと、
前記組織内の複数の位置における関心細胞の代謝活性を示す較正値を計算するステップであって、該較正値が前記生の値を前記組織内の複数の位置の各々における前記関心細胞の特定された分布に基づいて補正することにより得られる、計算するステップと
を有する、請求項2に記載のコンピュータの作動方法。 - 前記放射線画像を、前記組織内の複数の位置における関心細胞の代謝活性を示す前記較正値を示すように修正するステップを更に有する、請求項3に記載のコンピュータの作動方法。
- 前記組織が癌細胞を有すると疑われる、請求項1から4の何れか一項に記載のコンピュータの作動方法。
- 前記関心細胞が癌細胞及び/又はエフェクタT細胞を有する、請求項5に記載のコンピュータの作動方法。
- 前記組織の生物学的パラメータを示す前記生の値が、(18-F)フルオロデオキシグルコースを使用したポジトロン放出断層撮影法の撮像により取得される標準集積値である、請求項1から6の何れか一項に記載のコンピュータ実施方法。
- 前記顕微鏡画像が生検又は前記組織からの切除された組織サンプルの組織化学的及び/又は免疫組織化学的染色によって得られる、請求項1から7の何れか一項に記載のコンピュータの作動方法。
- 前記関心細胞の分布は、関心細胞の密度である、請求項1から8の何れか一項に記載のコンピュータの作動方法。
- 前記関心細胞が、プログラムされた細胞死リガンド1を過剰発現させる癌細胞を有する、請求項1から9の何れか一項に記載のコンピュータの作動方法。
- 前記生物学的パラメータが細胞マーカの発現を有する、請求項1から10の何れか一項に記載のコンピュータの作動方法。
- 前記細胞マーカが、プログラムされた細胞死リガンド1である、請求項11に記載のコンピュータの作動方法。
- 被検者の組織に関連する放射線データを較正するためのシステムであって、
前記組織の放射線画像及び該組織の顕微鏡画像を受信するためのインターフェースと、
メモリと、
プロセッサと
を有し、前記プロセッサは前記メモリに記憶された命令を実行して、
(i)前記放射線画像から前記組織内の生物学的パラメータを示す生の値を計算し、
(ii)前記顕微鏡画像から前記組織内の関心細胞の分布を特定し、
(iii)前記組織内の関心細胞の生物学的パラメータを示す較正値を、前記生の値を前記組織内の関心細胞の前記特定された分布に基づいて補正することにより計算し、
前記放射線画像が、ポジトロン放出断層撮影法により取得され、
前記組織の前記生物学的パラメータを示す前記生の値が、ポジトロン放出断層撮影法の撮像により取得される標準集積値である、
システム。 - コンピュータ又はプロセッサにより実行された場合に該コンピュータ又はプロセッサに請求項1から12の何れか一項に記載のコンピュータの作動方法を実行させるコンピュータ可読コードを有する、非一時的コンピュータ可読媒体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19150208.7 | 2019-01-03 | ||
EP19150208.7A EP3677185A1 (en) | 2019-01-03 | 2019-01-03 | Calibrating radiological data based on cell distribution |
PCT/EP2019/086998 WO2020141137A1 (en) | 2019-01-03 | 2019-12-24 | Calibrating radiological data based on cell distribution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022508462A JP2022508462A (ja) | 2022-01-19 |
JP7069423B2 true JP7069423B2 (ja) | 2022-05-17 |
Family
ID=64959234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021539004A Active JP7069423B2 (ja) | 2019-01-03 | 2019-12-24 | 細胞分布に基づく放射線データの較正 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220067939A1 (ja) |
EP (2) | EP3677185A1 (ja) |
JP (1) | JP7069423B2 (ja) |
CN (1) | CN113260311A (ja) |
WO (1) | WO2020141137A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060097175A1 (en) | 2004-11-10 | 2006-05-11 | General Electric Company | Method and system for imaging a patient |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5281517A (en) * | 1985-11-04 | 1994-01-25 | Cell Analysis Systems, Inc. | Methods for immunoploidy analysis |
US6483948B1 (en) * | 1994-12-23 | 2002-11-19 | Leica Ag | Microscope, in particular a stereomicroscope, and a method of superimposing two images |
US7383076B2 (en) * | 2000-11-27 | 2008-06-03 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
US20050136509A1 (en) * | 2003-09-10 | 2005-06-23 | Bioimagene, Inc. | Method and system for quantitatively analyzing biological samples |
CN1891155A (zh) * | 2006-05-26 | 2007-01-10 | 北京思创贯宇科技开发有限公司 | 一种基于ct图像的组织成分分析方法 |
US20100121172A1 (en) * | 2008-11-12 | 2010-05-13 | Siemens Corporate Research, Inc. | Microscopic and macroscopic data fusion for biomedical imaging |
WO2012068142A2 (en) * | 2010-11-15 | 2012-05-24 | Tissuevision, Inc. | Systems and methods for imaging and processing tissue |
US8711149B2 (en) * | 2010-12-08 | 2014-04-29 | Definiens Ag | Graphical user interface for interpreting the results of image analysis |
US20140242600A1 (en) * | 2011-06-08 | 2014-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging the heterogeneous uptake of radiolabeled molecules in single living cells |
US9478022B2 (en) * | 2011-08-22 | 2016-10-25 | Siemens Medical Solutions Usa, Inc. | Method and system for integrated radiological and pathological information for diagnosis, therapy selection, and monitoring |
CN103126711A (zh) * | 2012-12-27 | 2013-06-05 | 李华 | 便携式显微ct机x射线成像系统 |
CN105283780A (zh) * | 2013-03-15 | 2016-01-27 | 俄亥俄州创新基金会 | 用于信号不均匀性校正和性能评估的方法和装置 |
CN105163684B (zh) * | 2013-03-15 | 2018-02-02 | 圣纳普医疗(巴巴多斯)公司 | 手术数据的联运同步 |
CN105979872A (zh) * | 2013-09-25 | 2016-09-28 | 理查德·R·布莱克 | 正电子发射断层摄影数据的病人特异性分析 |
EP3209202B1 (en) * | 2014-10-20 | 2024-01-24 | New York University | Apparatus to select radiation dosage for tumor treatment based on cellular imaging |
CN205031282U (zh) * | 2015-09-17 | 2016-02-17 | 武汉瑞福宁科技有限公司 | 一种用于体外细胞放射性核素实验的平板pet系统 |
-
2019
- 2019-01-03 EP EP19150208.7A patent/EP3677185A1/en not_active Withdrawn
- 2019-12-24 US US17/419,751 patent/US20220067939A1/en active Pending
- 2019-12-24 EP EP19827759.2A patent/EP3905955B1/en active Active
- 2019-12-24 JP JP2021539004A patent/JP7069423B2/ja active Active
- 2019-12-24 WO PCT/EP2019/086998 patent/WO2020141137A1/en unknown
- 2019-12-24 CN CN201980087784.7A patent/CN113260311A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060097175A1 (en) | 2004-11-10 | 2006-05-11 | General Electric Company | Method and system for imaging a patient |
Non-Patent Citations (1)
Title |
---|
Mitsuru IZUMISAWA et al.,"The relationship between histopathological findings in oral squamous cell carcinoma and FDG uptake on PET",Oral Radiology,2003年,19;149-157 |
Also Published As
Publication number | Publication date |
---|---|
CN113260311A (zh) | 2021-08-13 |
EP3905955B1 (en) | 2022-07-27 |
WO2020141137A1 (en) | 2020-07-09 |
EP3905955A1 (en) | 2021-11-10 |
EP3677185A1 (en) | 2020-07-08 |
JP2022508462A (ja) | 2022-01-19 |
US20220067939A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis | |
Berghmans et al. | Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project | |
Ibrahim et al. | Radiomics analysis for clinical decision support in nuclear medicine | |
US8787643B2 (en) | Functional imaging | |
US20080240527A1 (en) | Methods, Compositions and Systems for Analyzing Imaging Data | |
Zaizen et al. | Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy | |
NL2010492C2 (en) | Systems and methods for attenuation compensation in nuclear medicine imaging based on emission data. | |
Differding et al. | PET imaging biomarkers in head and neck cancer | |
Visvikis et al. | The age of reason for FDG PET image-derived indices | |
Murphy et al. | Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity | |
JP2015518197A (ja) | 医用イメージングと生検データとを統合する臨床ワークステーション及びこれを使用する方法 | |
US11335464B2 (en) | Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making | |
Hildebrandt et al. | A role of FDG-PET/CT for response evaluation in metastatic breast cancer? | |
Mapelli et al. | 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry | |
Weng et al. | Deep learning-based segmentation of the lung in MR-images acquired by a stack-of-spirals trajectory at ultra-short echo-times | |
WO2019161220A1 (en) | Hepatic inflammation analysis with dynamic pet | |
Takahashi et al. | Correlation between positron emission tomography findings and glucose transporter 1, 3 and L‑type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas | |
JP7069423B2 (ja) | 細胞分布に基づく放射線データの較正 | |
Quarta et al. | Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice | |
Jennings et al. | PET‐specific parameters and radiotracers in theoretical tumour modelling | |
US20220262465A1 (en) | Radiology-based risk assessment for biopsy-based scores | |
US10755408B2 (en) | Medical information processing system and medical information processing apparatus | |
Khalil | Basics and advances of quantitative PET imaging | |
Frings et al. | Methodological Considerations in Quantification of 3'-Deoxy-3'-[18 F] Fluorothymidine Uptake Measured with Positron Emission Tomography in Patients with Non-Small Cell Lung Cancer | |
Gallamini et al. | Functional imaging in Hodgkin lymphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210702 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220315 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220502 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7069423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |